Drug Trial Radar · NCT07900373
Echinocandin Added to Standard Treatment for Severe Pneumocystis Pneumonia
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
416
Planned (sponsor's estimate)
Start
Apr 1, 2027
Primary completion
Apr 1, 2032
Study completion Dec 31, 2032
Sponsor
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Preclinical studies and retrospective clinical data suggest that adjunctive echinocandin therapy may improve outcomes in adults with severe Pneumocystis jirovecii pneumonia (PCP). However, the benefit of adding an echinocandin to standard PCP treatment has not been established in a definitive randomized controlled trial. The aim of this trial is: 1\. In adults hospitalized with severe PCP, to determine whether adding an echinocandin to standard anti-PCP therapy improves net clinical outcomes by Day 30 compared with standard anti-PCP therapy plus matching placebo.
Conditions
- Pneumocystis Jirovecii Pneumonia
Interventions
EchinocandinsDrug
Caspofungin 70 mg IV Day 1, then 50 mg daily; micafungin 100 mg IV daily; or anidulafungin 200 mg IV Day 1, then 100 mg daily.
Placebo (0.9% Sodium chloride) infusionDrug
0.9% sodium chloride IV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hierarchical Composite Clinical Outcome Assessed Using the Win Odds/Win RatioTime frame: Day 30
Locations
1 site in 1 country. Site status is shown where the registry gives one.
McGill University Health Centre
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.